- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Antibody–drug conjugates in the treatment of lymphoid neoplasms ; volume:17 ; number:2 ; day:8 ; month:5 ; year:2024 ; pages:135-139 ; date:5.2024
Magazine of European Medical Oncology ; 17, Heft 2 (8.5.2024), 135-139, 5.2024
- Urheber
-
Neumeister, Peter
Prochazka, Katharina Theresa
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12254-024-00965-x
- URN
-
urn:nbn:de:101:1-2408051048405.663493716765
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Neumeister, Peter
- Prochazka, Katharina Theresa
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Correction to: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Correction to: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Correction to: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer